2145 Participants Needed

Patient-centered Care for Acute Kidney Injury

(COPE-AKI Trial)

Recruiting at 8 trial locations
BP
KA
SJ
Overseen BySusan J Copelli, MSHI
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to improve care for people with severe acute kidney injury (AKI) by comparing a special intervention, the Multimodal Intervention, against usual care. The intervention includes a study doctor, a nurse for guidance and education, and a pharmacist to review medications. Researchers seek to determine if this approach results in more days out of the hospital and better kidney health. Suitable candidates are adults who have experienced stage 2 or 3 AKI for at least two days without quick improvement. As an unphased trial, this study provides a unique opportunity to contribute to innovative care strategies for AKI.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the approach tested in the COPE-AKI study is generally safe for patients. This approach includes several components: doctors oversee care, nurses educate about kidney disease, and pharmacists review medications. While specific side effects are not listed, the study ensures the approach is both safe and effective. Since the study does not test a new drug or invasive procedure, the risk of harmful side effects is likely low. This type of care aims to improve kidney health without causing additional issues.12345

Why are researchers excited about this trial?

Researchers are excited about the multimodal intervention for acute kidney injury because it offers a comprehensive approach that current treatments typically don't include. Unlike standard care, which primarily focuses on medication management and follow-up, this intervention combines physician oversight, nurse navigation, and pharmacist-led medication review. The nurse navigator plays a crucial role in educating patients about kidney disease and coordinating their care, potentially leading to better outcomes. Additionally, the inclusion of a pharmacist to review and reconcile medications ensures that patients avoid harmful drug interactions, which is a unique feature compared to usual care. This integrated approach aims to improve patient recovery and long-term kidney health by addressing multiple aspects of care simultaneously.

What evidence suggests that this multimodal intervention is effective for acute kidney injury?

Research has shown that combining different treatments can improve recovery after acute kidney injury (AKI). In this trial, participants in the Multimodal Process of Care Intervention arm will receive a comprehensive approach involving study physician oversight, nurse navigator support, and pharmacist-led medication review. One study found that care bundles, similar to these combined treatments, reduced the need for dialysis. This suggests that collaboration among doctors, nurses, and pharmacists can manage AKI more effectively. By focusing on follow-up care, education, and medication review, these treatments aim to prevent further kidney problems and enhance recovery. Early results are promising, indicating better patient outcomes and fewer complications.14678

Who Is on the Research Team?

KA

Kaleab Abebe, PhD

Principal Investigator

Univerisity of Pittsburgh

PP

Paul Palevsky, MD

Principal Investigator

University of Pittsburgh

LF

Linda Fried, MD

Principal Investigator

University of Pittsburgh

SK

Sandy Kane-Gill, PharmD

Principal Investigator

University of Pittsburgh

Are You a Good Fit for This Trial?

The COPE-AKI trial is for adults over 18 with severe acute kidney injury (AKI) that's lasted at least two days. It's not for those with certain types of kidney diseases, end-stage kidney disease, serious lung or liver conditions, life expectancy under six months, pregnancy, cognitive impairment preventing consent, or if they're in another high-risk study.

Inclusion Criteria

I have stage 2 or 3 kidney injury that has lasted for more than 2 days.

Exclusion Criteria

You have trouble thinking clearly, as shown by a test called the Brief Confusion Assessment Method (bCAM).
Vulnerable populations:
Concurrent enrollment in a separate greater than minimal risk interventional trial
See 26 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a multimodal process-of-care intervention or usual care, including study physician oversight, nurse navigator involvement, and pharmacist-led medication reconciliation

90 days
Regular follow-up visits as per study protocol

Follow-up

Participants are monitored for hospital-free days and major adverse kidney events, with assessments of patient-reported outcomes

180 days
Follow-up visits at 90 and 180 days

Long-term Follow-up

Participants are monitored for long-term outcomes including recurrent AKI and quality of life measures

365 days

What Are the Treatments Tested in This Trial?

Interventions

  • Multimodal Intervention
Trial Overview This study compares a special care package including a doctor/advanced provider team-up, nurse navigator support, pharmacist involvement and patient education against the usual care given to AKI patients. The goal is to see if this approach increases the number of days patients stay out of the hospital after discharge.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Multimodal Process of Care InterventionExperimental Treatment4 Interventions
Group II: Usual CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pittsburgh

Lead Sponsor

Trials
1,820
Recruited
16,360,000+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Published Research Related to This Trial

The revised Patient Perception of Patient-Centeredness (PPPC-R) questionnaire, tested on 381 patients in Ontario, Canada, successfully identified a 3-factor model that effectively measures patient-centered care, demonstrating good statistical fit and validity.
While the PPPC-R aligns with the Patient-Centered Clinical Method (PCCM) framework, it reflects the patient's actual experience of care rather than a direct correspondence, highlighting the importance of patient perspectives in evaluating healthcare quality.
Measuring Patients' Perceptions of Health Care Encounters: Examining the Factor Structure of the Revised Patient Perception of Patient-Centeredness (PPPC-R) Questionnaire.Ryan, BL., Brown, JB., Tremblay, PF., et al.[2022]
The review identified three key factors that facilitate patient-centred care in acute healthcare settings: effective patient care practices, educational initiatives for both staff and patients, and supportive organizational policies.
Implementing these evidence-based guidelines can enhance the quality of care by promoting better communication, family involvement, and interdisciplinary collaboration among healthcare providers.
Integrative literature review of evidence-based patient-centred care guidelines.Jardien-Baboo, S., van Rooyen, DRM., Ricks, EJ., et al.[2021]
A scoping review of 98 studies identified key elements of patient-centered interventions that can improve health outcomes for patients with multimorbidity, emphasizing the importance of supporting patient self-management and decision-making processes.
The review suggests that integrating patient-oriented approaches, interdisciplinary teamwork, and training for healthcare providers can significantly enhance care for individuals with multiple chronic conditions, leading to better health management strategies.
What are the effective elements in patient-centered and multimorbidity care? A scoping review.Poitras, ME., Maltais, ME., Bestard-Denommé, L., et al.[2018]

Citations

Effect of acute kidney injury care bundles on patient ...Seven studies reported the application of renal replacement therapy after AKI care bundle interventions, with 64 out of 2,774 patients in the ...
Study Details | NCT05805709 | A Patient-centered Trial of ...Key secondary outcomes include: rates of MAKE (measured at 90, 180, and 365 days), rates of recurrent AKI (90, 180, and 365 days), and 4 patient-report outcomes ...
Patient-centered Care for Acute Kidney InjuryThe COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of ...
Forecasting acute kidney injury and resource utilization in ...Our study revealed the importance and the technicality of applying longitudinal, multimodal modeling to improve early prediction of AKI and CRRT, offering ...
Artificial intelligence models for predicting acute kidney injury ...This review comprehensively assesses the modeling methods, data utilization strategies, and clinical applicability of AKI prediction models in the ICU
Forecasting Acute Kidney Injury and Resource Utilization in ...Our study revealed the importance and the technicality of applying longitudinal, multimodal modeling to improve early prediction of AKI and CRRT, offering ...
Assessments of Generative Artificial Intelligence as Clinical ...Clinical interventions that prevent or reduce AKI severity include altering medication and contrast administration, treating underlying sepsis, ...
A narrative review of the impact of interventions in acute ...This narrative review discusses reactive interventions and their impact on the progression and severity of AKI, and on mortality from it.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security